药物洗脱球囊和药物洗脱支架在周围血管疾病治疗中的应用
Drug-Eluting Balloons and Drug-Eluting Stents in the Treatment of Peripheral Vascular Disease.
作者信息
Lindquist Jonathan, Schramm Kristofer
机构信息
Division of Vascular and Interventional Radiology, Department of Radiology, University of Colorado, Aurora, Colorado.
出版信息
Semin Intervent Radiol. 2018 Dec;35(5):443-452. doi: 10.1055/s-0038-1676360. Epub 2019 Feb 5.
Abstract
In the last 20 years, peripheral artery disease (PAD) has been increasingly recognized as a significant cause of morbidity and mortality in the United States. The endovascular treatment of PAD has seen a marked rise as minimally invasive techniques and devices have been refined. Two newer devices, drug-eluting stents and drug-eluting balloons, are on the forefront of the battle against limb loss from PAD. This review focuses on the data backing the use of drug-eluting technologies for use in the peripheral arterial system.
摘要
在过去20年里，外周动脉疾病（PAD）在美国已日益被视为发病和死亡的一个重要原因。随着微创技术和器械的不断完善，PAD的血管内治疗显著增加。两种较新的器械，药物洗脱支架和药物洗脱球囊，处于对抗PAD导致肢体丧失的前沿。本综述重点关注支持在外周动脉系统中使用药物洗脱技术的数据。
相似文献
1
Drug-Eluting Balloons and Drug-Eluting Stents in the Treatment of Peripheral Vascular Disease.药物洗脱球囊和药物洗脱支架在周围血管疾病治疗中的应用
Semin Intervent Radiol. 2018 Dec;35(5):443-452. doi: 10.1055/s-0038-1676360. Epub 2019 Feb 5.
2
Paclitaxel-Coated Balloons and Eluting Stents: Is There a Mortality Risk in Patients With Peripheral Artery Disease?紫杉醇涂层球囊和药物洗脱支架：外周动脉疾病患者的死亡率存在风险吗？
Circulation. 2019 Oct 15;140(16):1342-1351. doi: 10.1161/CIRCULATIONAHA.119.041099. Epub 2019 Jun 10.
3
Is There a Safety Concern for Drug-Coated Balloons in Peripheral Arterial Disease?药物涂层球囊在治疗外周动脉疾病中的安全性问题探讨
Curr Cardiol Rep. 2019 Sep 7;21(10):126. doi: 10.1007/s11886-019-1211-z.
4
Drug eluting devices for critically ill patients: can we apply lessons learned from the treatment of peripheral artery disease?药物洗脱装置在危重症患者中的应用：我们能否借鉴外周动脉疾病治疗中的经验教训？
Adv Drug Deliv Rev. 2014 Nov 20;77:32-9. doi: 10.1016/j.addr.2014.07.005. Epub 2014 Jul 16.
5
Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment.外周动脉疾病中的紫杉醇药物洗脱支架：一项卫生技术评估。
Ont Health Technol Assess Ser. 2015 Nov 1;15(20):1-62. eCollection 2015.
6
Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.药物涂层球囊改善股腘动脉通畅性：LEVANT 2试验的原理与设计
Am Heart J. 2015 Apr;169(4):479-85. doi: 10.1016/j.ahj.2014.11.016. Epub 2014 Dec 20.
7
Drug-eluting stents for PAD: what does (all) the data tell us?用于外周动脉疾病的药物洗脱支架：（所有）数据告诉了我们什么？
J Cardiovasc Surg (Torino). 2019 Aug;60(4):433-438. doi: 10.23736/S0021-9509.19.10965-2. Epub 2019 Apr 30.
8
Techniques in Vascular and Interventional Radiology Drug Delivery Technologies in the Superficial Femoral Artery.血管与介入放射学技术：股浅动脉中的药物递送技术
Tech Vasc Interv Radiol. 2016 Jun;19(2):145-52. doi: 10.1053/j.tvir.2016.04.007. Epub 2016 May 5.
9
Peripheral Vascular Restenosis: A Retrospective Study on the Use of Drug-Eluting Balloons in Native Arteries, Vein Grafts and Dialysis Accesses.外周血管再狭窄：关于药物洗脱球囊在原生动脉、静脉移植物和透析通路中应用的回顾性研究
Scand J Surg. 2017 Jun;106(2):158-164. doi: 10.1177/1457496916654098. Epub 2016 Jun 7.
10
Drug-eluting stents and balloons in peripheral arterial disease: evidence so far.药物洗脱支架和外周动脉疾病中的球囊：迄今为止的证据。
Int J Clin Pract. 2011 Jun;65(6):664-8. doi: 10.1111/j.1742-1241.2011.02639.x.
引用本文的文献
1
Computational modeling of drug-eluting balloons in peripheral artery disease: Mechanisms, optimization, and translational insights.外周动脉疾病中药物洗脱球囊的计算建模：机制、优化及转化见解。
Comput Struct Biotechnol J. 2025 Aug 7;27:3640-3653. doi: 10.1016/j.csbj.2025.08.005. eCollection 2025.
2
Drug-coated balloons versus conventional percutaneous transluminal angioplasty for treatment-naïve dysfunctional arteriovenous fistulas.: A 10-year single center retrospective study.药物涂层球囊与传统经皮腔内血管成形术治疗初治功能不良动静脉瘘：一项 10 年单中心回顾性研究。
Saudi Med J. 2024 Jul;45(7):741-744. doi: 10.15537/smj.2024.45.7.20230852.
3
Drug-Coated Balloon versus Drug-Eluting Stent: The Debate of Leave Nothing Behind.药物涂层球囊与药物洗脱支架：不留任何隐患的争论
Semin Intervent Radiol. 2023 Jun 16;40(2):161-166. doi: 10.1055/s-0043-57261. eCollection 2023 Apr.
4
Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process.利用纳米颗粒干扰血管供应和血管生成过程治疗难治性疾病。
Eur J Med Res. 2022 Nov 4;27(1):232. doi: 10.1186/s40001-022-00833-6.
5
Slow-flow phenomena following lower limb paclitaxel- and sirolimus-coated balloon angioplasty in the setting of chronic limb threatening ischaemia-a case series.慢性肢体威胁性缺血情况下下肢紫杉醇和西罗莫司涂层球囊血管成形术后的慢血流现象——病例系列
Quant Imaging Med Surg. 2022 Mar;12(3):2058-2065. doi: 10.21037/qims-21-633.
6
A homogenized constrained mixture model of restenosis and vascular remodelling after balloon angioplasty.球囊血管成形术后再狭窄和血管重塑的均匀化约束混合模型。
J R Soc Interface. 2021 May;18(178):20210068. doi: 10.1098/rsif.2021.0068. Epub 2021 May 5.
7
Drug-Eluting Stents and Balloons-Materials, Structure Designs, and Coating Techniques: A Review.药物洗脱支架和球囊-材料、结构设计和涂层技术：综述。
Molecules. 2020 Oct 11;25(20):4624. doi: 10.3390/molecules25204624.
8
Is There a Safety Concern for Drug-Coated Balloons in Peripheral Arterial Disease?药物涂层球囊在治疗外周动脉疾病中的安全性问题探讨
Curr Cardiol Rep. 2019 Sep 7;21(10):126. doi: 10.1007/s11886-019-1211-z.
本文引用的文献
1
Next Generation Endovascular Therapies in Peripheral Artery Disease.外周动脉疾病的下一代血管内治疗。
Prog Cardiovasc Dis. 2018 Mar-Apr;60(6):593-599. doi: 10.1016/j.pcad.2018.03.003. Epub 2018 Mar 10.
2
Lutonix® 014 DCB global Below the Knee Registry Study: interim 6-month outcomes.Lutonix® 014药物涂层球囊全球膝下注册研究：6个月中期结果
J Cardiovasc Surg (Torino). 2018 Apr;59(2):232-236. doi: 10.23736/S0021-9509.18.10269-2. Epub 2018 Jan 23.
3
Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.药物涂层球囊在股浅动脉中 3 年的疗效持久：IN.PACT SFA 随机试验的长期结果。
Circ Cardiovasc Interv. 2018 Jan;11(1):e005891. doi: 10.1161/CIRCINTERVENTIONS.117.005891.
4
Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.药物涂层球囊治疗股腘动脉疾病：IN.PACT 全球研究初次支架内再狭窄成像队列。
JACC Cardiovasc Interv. 2017 Oct 23;10(20):2113-2123. doi: 10.1016/j.jcin.2017.06.018.
5
Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up.Eluvia紫杉醇洗脱支架治疗股腘动脉疾病的MAJESTIC试验的长期结果：3年随访
Cardiovasc Intervent Radiol. 2017 Dec;40(12):1832-1838. doi: 10.1007/s00270-017-1771-5. Epub 2017 Sep 25.
6
Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.定向旋切术联合紫杉醇涂层球囊抑制再狭窄和维持管腔通畅：DEFINITIVE AR 研究的 12 个月结果。
Circ Cardiovasc Interv. 2017 Sep;10(9):e004848. doi: 10.1161/CIRCINTERVENTIONS.116.004848.
7
The 24-Month Results of the Lutonix Global SFA Registry: Worldwide Experience With Lutonix Drug-Coated Balloon.《 Lutonix 全球 SFA 注册研究 24 个月结果： Lutonix 药物涂层球囊的全球应用经验》
JACC Cardiovasc Interv. 2017 Aug 28;10(16):1682-1690. doi: 10.1016/j.jcin.2017.04.041. Epub 2017 Aug 2.
8
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.用于治疗股腘动脉疾病的Stellarex药物涂层球囊：随机ILLUMENATE关键和药代动力学研究的12个月结果
Circulation. 2017 Sep 19;136(12):1102-1113. doi: 10.1161/CIRCULATIONAHA.117.028893. Epub 2017 Jul 20.
9
Impact of Fluoropolymer-Based Paclitaxel Delivery on Neointimal Proliferation and Vascular Healing: A Comparative Peripheral Drug-Eluting Stent Study in the Familial Hypercholesterolemic Swine Model of Femoral Restenosis.载紫杉醇氟聚合物对新生内膜增殖和血管愈合的影响：家族性高胆固醇血症猪股部再狭窄模型中外周药物洗脱支架的对比研究。
Circ Cardiovasc Interv. 2017 May;10(5). doi: 10.1161/CIRCINTERVENTIONS.116.004450.
10
Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis.紫杉醇涂层球囊与非涂层球囊血管成形术治疗股腘动脉支架内再狭窄。
Int J Surg. 2017 Jun;42:72-82. doi: 10.1016/j.ijsu.2017.04.057. Epub 2017 Apr 29.
Zotero 插件